GLP-1 injections, such as semaglutide (Ozempic) or tirzepatide (Mounjarno or Zepbound), are administered just under the skintypically in areas like the abdomen, thigh, or upper arm
[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
Glossary CKD c hronic kidney disease CNS central nervous system CVD c ardiovascular disease FDA Food and Drug Administration GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HF Heart failure MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PAD peripheral arterial disease SC subcutaneous T2DM type 2 diabetes mellitus U.S
Osei SP, Akomaning E, Florut TF, Sodhi M, Lacy BE, Aldhaleei WA, et al